Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative aromatase inhibitor (AI) monotherapy in MBC patients. | Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer Results of the prospective observational EvAluate-TM study
